- Our products
- Your eye health
- Research & Innovation
- Fondation Théa
To consolidate its presence on the front of research and innovation, Théa participates in all national and international congresses and meetings dedicated to ophthalmology and opted to partner many subspecialty meetings.
Congresses, conferences, product launches, scientific innovation, innovation, new offices, Théa is always on the move.
The leading European ophthalmology pharmaceutical company is the first to offer an innovative hyaluronic acid treatment for the management of dry eye.
Education and knowledge sharing have always been a tradition for the Chibret family. That's why Théa supports many educational projects and activities.
Dry eye, also known as dry eye disease, dry eye syndrome or keratoconjunctivitis sicca (KCS), is one of the most frequent reasons people see an ophthalmologist.
Henri Chibret received the "Spirit of Helen Keller Award", honouring his major contribution to ophthalmology research and prevention of blindness worldwide.
Théa continues its international expansion in the American continent and opens a new subsidiary in the United States.
Théa belongs to a select circle of pharmaceutical companies with subsidiaries at the continent’s four cardinal points. Throwback to Théa's European construction.
World Glaucoma Week (March 7-13) is a global initiative of the World Glaucoma Association (WGA) to raise awareness on glaucoma.
Théa, the leading European pharmaceutical group in ophthalmology (excluding the retina market), increases its research and clinical trials capacity by doubling its innovation space footprint at the headquarters in Clermont-Ferrand.
The 14th EGS Resident Course held 18–19th September in Lisbon featured a series of DryLab sessions where internationally-acclaimed faculty supervised hands-on glaucoma surgery training for young ophthalmologists from across Europe.
BIOCORP and Laboratoires Théa sign a partnership for the development of innovative digital solutions.
We live in a beautiful world, but not everyone can see it. 253 million people suffer from vision impairment and 36 million are blind or going blind. Yet, 80% of all vision impairment can now be prevented, treated or cured.
Théa organized DryLab session workshops dedicated specifically for young ophthalmologists from 23 different countries, at this year’s big SOE conference.
More than 100 ophthalmologists from 18 countries attended the 5th ENM forum on the latest news and developments in ocular health.
This year marks Théa’s 25th anniversary and we are taking this opportunity to update our identity. “let’s open our eyes” becomes Théa’s new signature around the world.
The 7th Théa TROPHY contest award ceremony took place in Vancouver at ARVO 2019.
World Glaucoma Week is now right around the corner (from March 10 to 16) and we need to get people to talk about it!
Over one hundred international dry eye experts will be meeting this Friday at the Institute of Ocular Microsurgery (IMO) to take part in an “Ocular Surface Masterclass,” to present and put into practice the latest advancements in dealing with dry eye disease.
Théa brought together the thirteen national winners of the 6th clinical case contest, TROPHY, in Nice from October 3 to 6, 2018.
Most of the things we take for granted today did not just happen. In this new book of the Théa Medical Library collection, Professor Harminder S. DUA and Mr. Richard KEELER take us on a journey through the history of ophthalmic instruments and treatments.
After Central America (Mexico), the Group is expanding into South America. On April 19, 2018, Mr. Roland DUBERTRAND, ambassador of France to Chile, celebrated the creation of Théa's new Chilean subsidiary.
220 young ophthalmologists from more than 21 countries submitted clinical cases in answer to the topic of the sixth edition of the TROPHY contest – ‘novel management of ocular surface diseases’.
Laboratoires THEA attended the 13th European Glaucoma Society (EGS) Congress which took place in Florence, Italy from 19 to 22 May 2018.
Thea UK were delighted to support the Thea Birmingham Corneal Meeting recently.
During 2 vital national conferences; Théa France organised its first DRY LAB workshops dedicated to young ophthalmologists.
Laboratoires THEA participated in the 22nd European Society of Cataract and Refractive Surgeons (ESCRS) Winter Meeting, which took place in Belgrade, Serbia, from 9 to 11 February 2018, a great opportunity to meet Eastern Europe's ophthalmologists.
For the seventh consecutive year, Théa organised a France/Maghreb meeting with Dr Lazreg & Dr Santiago on the theme of surgical retina. 400 ophthalmologists participated in this event at the 18th Ophthalmological Reflections Days in Paris.
116 young ophthalmologists from over 21 countries submitted a clinical case in response to the subject chosen for the TROPHY 5th edition: “The non-surgical treatment of corneal diseases”.
The Fareva group, and more specifically its subsidiary Excelvision, has opened a new single-dose sterile production unit with Théa Laboratories. This new building will be capable of manufaturing 800 million preservative-free single doses per year, as opposed to the 500 million produced today.
Following Mexico in 2014, Morocco and Russia in 2015 and Ukraine in 2016, it is now Dubai’s turn to witness the opening of a new subsidiary of Théa Laboratories.
90 ophthalmologists from 14 different countries attended a Théa event on the latest developments in eye health, including the benefits of nutrition, predominantly vitamin D.
A new simple and fast questionnaire has been developed by Laboratoires Théa in order to assess early AMD risk.
Thanks to many years of experience and intense research, Théa has found a new way to generate faster and stable dilation. Taking the opportunity of the ESCRS international congress, Théa shared this innovation with several thousand ophthalmologists coming from all over Europe.
European ophthalmological professors have joined together in order to present an all-encompassing book on the complicated topic of Chronic Corneal Ulcers.
This book is aimed at ophthalmologists in order to improve cornea care.
Written by Lorraine Kaltenbach under the direction of Henri Chibret, this saga relates the history of the Chibret’s family since the French revolution up until today; but above all the close relationship that family members have always maintained
with ophthalmological workers.
Founded in 2001, Théa PHARMA Switzerland began their journey with only 2 products.
Today their range of both innovative and well-known products covers almost every ophthalmological therapeutic class.
The second edition of the European Meeting of Young Ophthalmologists took place in June in Oviedo, Spain. Laboratoires Théa, represented by Jean-Frédéric Chibret, the President of the company, was the main partner and sponsor of the event.
Théa is very keen on innovating in all therapeutic areas in ophthalmology, including cataract surgery.
To develop its new product indicated in the mydriasis (pupil dilation) for patients undergoing cataract surgery, Théa set up clinical studies to demonstrate the efficacy and the safety of the product.
After Mexico in 2014, Morocco and Russie in 2015, it is now in Ukraine that Théa has opened their latest new representative office.The Ambassador of France in Ukraine, Isabelle Dumont, Prof. Vitovska, the Head of Ukrainian ophthalmologists and
Jean-Frédéric Chibret, President of Théa, were present for this event.
The Théa story in Belgium started in 2000 when Théa accepted the challenge to break new ground in preservative-free eye care in Benelux.
Supporting the integration and mobility of employees across the Group is Théa’s aspiration to ensure the career development of each individual.
Preservative-free is in the DNA of Laboratoires Théa and is part of its history. Increase the awareness of the ophthalmologists to the importance of Preservative-free eye drops remains a priority with one goal: 0% Preservatives.
Innovation in the area of preservative-free eye drops is one of the most important interests of Théa’s research and development.
Théa Pharma Germany presented the new Théa preservative-free association of two anti-glaucoma active ingredients at the DOG congress in Düsseldorf in March 2016. This product is distributed in a multidose bottle using EasyGrip® technology.